Archives

The study evaluates the efficacy and safety of the R21 malaria vaccine candidate (Jenner Institute, University of Oxford) formulated with the Matrix-M adjuvant (Novavax) in a phase 1–2a malaria [...]

The use of an appropriate adjuvant is crucial for developing an effective HIV vaccine. This study investigates the efficacy of QS-21-based saponin/monophosphoryl lipid A nanoparticle (SMNP) and [...]

The article explores the promising role of phytochemicals, particularly saponins like Quil A and its derivative QS-21 from Quillaja saponaria, in enhancing cancer immunotherapy.

Bovine colostrum has the potential to serve as a source of neutralizing antibodies for preventing viral infections due to the evolutionary homology between bovine and human immunoglobulins.

The study evaluated the stability of two recombinant Cytomegalovirus antigens (gB and Pentamer) formulated with the SPA14 adjuvant system, a liposomal formulation containing QS-21 and the [...]

Desert King® (DK) and the Vaccine Formulation Institute (VFI) have joined forces in a strategic alliance to revolutionize global access to vaccine adjuvants.

Desert King®, a global leader in the vaccine adjuvant market based on Quillaja saponaria saponins, is proud to announce his EXCiPACT™ certification.